ADReCS

Pharmaceutical Information

Drug Name	Propranolol
Drug ID	BADD_D01867
Description	Propranolol is a racemic mixture of 2 enantiomers where the S(-)-enantiomer has approximately 100 times the binding affinity for beta adrenergic receptors.[L6904] Propranolol is used to treat a number of conditions but most commonly is used for hypertension.[L6901,L6904,L6907] Propranolol was granted FDA approval on 13 November 1967.[L6904]
Indications and Usage	Propranolol is indicated to treat hypertension.[L6907,L6904] Propranolol is also indicated to treat angina pectoris due to coronary atherosclerosis, atrial fibrillation, myocardial infarction, migraine, essential tremor, hypertrophic subaortic stenosis, pheochromocytoma, and proliferating infantile hemangioma.[L6904,L6907]
Marketing Status	approved; investigational
ATC Code	C07AA05
DrugBank ID	DB00571
KEGG ID	D08443
MeSH ID	D011433
PubChem ID	4946
TTD Drug ID	D04JEE
NDC Product Code	Not Available
UNII	9Y8NXQ24VQ
Synonyms	Propranolol \| Propanolol \| Inderal \| Avlocardyl \| AY-20694 \| AY 20694 \| AY20694 \| Rexigen \| Dexpropranolol \| Dociton \| Obsidan \| Obzidan \| Propranolol Hydrochloride \| Hydrochloride, Propranolol \| Anaprilin \| Anapriline \| Betadren

Chemical Information

Molecular Formula	C16H21NO2
CAS Registry Number	525-66-6
SMILES	CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Peripheral arterial occlusive disease	24.04.03.010	-	-	Not Available
Hypophagia	14.03.01.006; 07.01.06.010; 19.09.01.004	0.000315%		Not Available
Dark circles under eyes	08.01.03.054; 06.08.03.019	0.000118%		Not Available
Neuropsychological test abnormal	13.07.06.001	-	-	Not Available
Bronchial hyperreactivity	22.03.01.016	0.000160%		Not Available
Treatment failure	08.06.01.017	0.000710%		Not Available
Liver injury	12.01.17.012; 09.01.07.022	0.000080%		Not Available
Regurgitation	07.01.07.004	0.000272%		Not Available
Brain injury	19.07.03.007; 17.11.01.003	0.000053%		Not Available
Oropharyngeal discomfort	22.12.03.015; 07.05.05.008	-	-	Not Available
Oropharyngeal pain	22.12.03.016; 07.05.05.004	0.000331%
Mechanical urticaria	23.04.02.004; 10.01.06.004	0.000053%		Not Available
Hypoxic-ischaemic encephalopathy	24.04.06.021; 22.02.02.011; 17.13.02.006	0.000053%		Not Available
Foetal growth restriction	18.03.01.002	0.000240%
Slow speech	19.19.02.004; 17.02.08.016	0.000053%		Not Available
Substance-induced psychotic disorder	19.03.01.007; 12.03.01.053	0.000187%		Not Available
Faeces soft	07.01.03.008	0.000272%		Not Available
Encapsulating peritoneal sclerosis	07.07.03.004	0.000053%		Not Available
Respiratory symptom	22.12.02.013	0.000235%		Not Available
Sinus node dysfunction	02.03.03.017	0.000134%
Feeding intolerance	18.04.11.003; 14.02.01.006	0.000107%		Not Available
Apnoeic attack	22.02.01.027; 17.02.05.051	0.000080%		Not Available
Coeliac disease	14.02.01.007; 10.04.04.012; 07.17.01.008	0.000235%		Not Available
Mesenteric vein thrombosis	24.01.08.004; 07.15.02.013	0.000053%		Not Available
Pupil fixed	17.02.11.008; 06.05.03.012	0.000080%		Not Available
Small for dates baby	18.04.02.002	0.000053%		Not Available
Wolff-Parkinson-White syndrome	02.03.01.016	0.000080%		Not Available
Accelerated idioventricular rhythm	02.03.04.017	0.000107%		Not Available
Bradycardia neonatal	02.03.02.019; 18.04.07.004	0.000187%		Not Available
Peripheral artery occlusion	24.04.03.022	-	-	Not Available

The 13th Page First Pre 13 14 Next Last Total 14 Pages